Genetic Diagnostic Centre

Belkins
Genetic Diagnostic Center is a leading Egyptian medical center dedicated to delivering innovative medical genetics services for patients and other healthcare providers. In GDC, we combine 50 years of experience with the latest cutting-edge technologies to offer a quality driven performance in Cytogenetics, Molecular Genetics, Hematopathology, Flow Cytometry and Immunohistochemistry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

news image

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More

RESEARCH

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

news image

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

news image

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More

INDUSTRIAL IMPACT

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

news image

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More
news image

AVM BIOTECHNOLOGY HAS FDA APPROVAL FOR CLINICAL TRIALS FOR PROMISING NEW CANCER TREATMENT

PR Newswire | April 14, 2020

Seattle's AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia. We are seeking patients to begin Phase I/II trials. Compassionate use will be considered under US FDA guidelines. More information can be found here: clinicaltrials.gov. AVM0703 works by supercharging and mobilizing the immune cells within all of us. When a patient is treated with AVM070...

Read More
news image

RESEARCH

CEDILLA THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS ACROSS R&D AND FINANCE

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...

Read More
news image

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More
news image

INDUSTRIAL IMPACT

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More